Skip to main content
SpringerLink
Log in
Book cover

Chronic Myeloid Leukemia pp 197–206Cite as

Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response

  • Chapter
  • First Online:

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Chronic myeloid leukemia (CML) is a demonstrative example of successful targeted therapy with tyrosine kinase inhibitors (TKI). The overall survival of CML patients who respond to TKI is now considered very close to that of the healthy population control. Several clinical trials have demonstrated that some patients with CML in chronic phase who achieve sustained deep molecular responses on TKI therapy can safely suspend therapy and attempt a new goal treatment-free remission (TFR). The number of patients eligible for such goal has increased to the point where the issue of TFR has become of utmost importance even for drug companies. It should be considered the future criterion to evaluate the success of clinical trials, especially if we want to take into account quality of life of patients and also the economic aspect.

The question of cure in CML is now one of the major concerns and has to be considered in the management of the disease.

Parts of this chapter have formerly been published within the journal Annals of Hematology in Volume 94, Issue 2, supplement, April 2015, “Chronic Myeloid Leukemia,” doi:10.1007/s00277-015-2320-4.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Berger MG, Pereira P, Oris C, Saugues S, Cony-Makhoul P, Gardembas M et al. (2015) Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): a French Cohort. ASH annual meeting abstracts; Abstract No. 137

    Google Scholar 

  • Biernaux C, Loos M, Sels A et al (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 8:3118–3122

    Google Scholar 

  • Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362–3367

    CAS  PubMed  Google Scholar 

  • Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080–7085

    Article  CAS  PubMed  Google Scholar 

  • Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCRABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818–3824

    Article  CAS  PubMed  Google Scholar 

  • Chen Y, Peng C, Sullivan C et al (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anti Cancer Agents Med Chem 10:111–115

    Article  CAS  Google Scholar 

  • Cortes J, O’Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204–2205

    Article  CAS  PubMed  Google Scholar 

  • Cross NCP, White H, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175

    Article  CAS  PubMed  Google Scholar 

  • Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29(5):999–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Deininger M (2011) Hematology: curing CML with imatinib—a dream come true? Nat Rev Clin Oncol 3:127–128

    Article  Google Scholar 

  • Dierks C, Beigi R, Guo GR et al (2008) Expansion of Bcr-Abl positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238–249

    Article  CAS  PubMed  Google Scholar 

  • Etienne G, Rea D, Guilhot J, Guilhot F, Huguet F, Legros L, Nicolini FE, Charbonnier A, Guerci A, Varet BR, Rousselot P, Mahon FX (2015) Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in chronic myeloid leukemia patients. Blood (ASH annual meeting abstracts) 126: [abstract 345]

    Google Scholar 

  • Falchi L, Kantarjian HM, Wang X et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024–1029

    Article  CAS  PubMed  Google Scholar 

  • Gallipoli P, Abraham SA, Holyoake TL (2011) Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin North Am 25:951–966

    Google Scholar 

  • Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1–7

    Article  CAS  PubMed  Google Scholar 

  • Hantschel O, Warsch W, Eckelhart E et al (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285–293

    Article  CAS  PubMed  Google Scholar 

  • Hehlmann R, Müller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415–423

    Article  PubMed  Google Scholar 

  • Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I (2013) Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121:378–384

    Article  CAS  PubMed  Google Scholar 

  • Hurtz C, HatziK CL et al (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208:2163–2174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ilander MM, Olsson-Strömberg U, Lähteenmäki H et al (2013) Disease relapse after TKI discontinuation in CML is related both to low number and impaired function of NK-cells: data from Euro-SKI. Blood (ASH annual meeting abstracts) 122(Suppl): [abstract 379)

    Google Scholar 

  • Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S, DADI Trial Group (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2(12):e528–e535

    Article  PubMed  Google Scholar 

  • Kleppe M, Levine RL (2012) Targeting beta-catenin in CML: leukemia stem cells beware! Cell Stem Cell 10:351–353

    Article  CAS  PubMed  Google Scholar 

  • Li L, Wang L, Li L et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266–281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mahon FX (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematol Am Soc Hematol Educ Program 2012:122–128

    Google Scholar 

  • Mahon FX, Delbrel X, Cony-Makhoul P et al (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214–220

    Article  CAS  PubMed  Google Scholar 

  • Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  • Mahon FX, Nicolini F, NoëlMP, Escoffre M, Charbonnier A, Rea D, Dubruille V, Varet B, Legros L, Guerci A, Etienne G, Guilhot F, Dulucq S, Rousselot P, Guilhot J (2013) Preliminary report of the STIM2 Study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH annual meeting abstracts) [abstract 654]

    Google Scholar 

  • Mahon FX, Baccarani M, Mauro M et al (2014) Treatment-free remission following nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath ASCO meeting 2014. J Clin Oncol 32:5s, (Suppl; abstr TPS7124)

    Google Scholar 

  • Mauro MJ, Druker BJ, Marziaz RT (2004) Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(S1):S71–S73

    Article  CAS  PubMed  Google Scholar 

  • Melo JV, Ross DM (2011) Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematol Am Soc Hematol Educ Program 2011:136–142

    Google Scholar 

  • Merante S, Orlandi E, Bernasconi P et al (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979–981

    PubMed  Google Scholar 

  • Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267–1270

    Article  CAS  PubMed  Google Scholar 

  • Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90(10):910–914

    Article  CAS  PubMed  Google Scholar 

  • National Comprehensive Cancer Network (2012) Chronic myelogenous leukemia. NCCN clinical practice guidelines in oncology; v1.2013. J Natl Compr Canc Netw 10:64–110

    Google Scholar 

  • Réa D, Rousselot P, Nicolini F, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F, Mahon FX (2011) Discontinuation of dasatinib or nilotinib in chronicmyeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FI-LMC) Blood (ASH) 2012: Abstract 9168. Rea D et al. Blood 118(21) [abstract 604]

    Google Scholar 

  • Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX (2012) Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7:103–108

    Article  PubMed  Google Scholar 

  • Rea D, Dulphy N, Henry G, J Guilhot J, Guilhot F, Franck E, Nicolini, Legros L, Rousselot Ph, Mahon FX, Toubert A (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators. Blood (ASH annual meeting abstracts) 122(Suppl): [abstract 856)

    Google Scholar 

  • Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B et al (2014) Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 32(25):2821–2823

    Article  PubMed  Google Scholar 

  • Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719–1724

    Article  CAS  PubMed  Google Scholar 

  • Ross DM, Branford S, Seymour JF, Arthur C, Schwarer AP, Dang P et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522

    Article  CAS  PubMed  Google Scholar 

  • Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58–60

    Article  CAS  PubMed  Google Scholar 

  • Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424–430

    Article  CAS  PubMed  Google Scholar 

  • Saussele S, Richter J, Guilhot J, Müller MC, Dietz C, Porkka K et al (2014) First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. 19th Congress of the European Hematology Association, Milan, June 12–15, 2014. Haematologica 99(Suppl 1):LB-6214

    Google Scholar 

  • Stein AM, Bottino D, Modur V et al (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 21:6812–6821

    Article  Google Scholar 

  • Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903–906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S et al (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36:689–693

    Article  CAS  PubMed  Google Scholar 

  • Zhang B, Strauss AC, Chu S et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17:427–442

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Bergonié Cancer Institute, 229 cours de l’Argonne, Bordeaux, 33076, France

    Francois-Xavier Mahon

  2. INSERM U916, University of Bordeaux, Bordeaux, France

    Francois-Xavier Mahon

  3. III. Med. Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Pettenkoferstr. 22, Mannheim, 68169, Germany

    Susanne Saußele

Authors
  1. Francois-Xavier Mahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Saußele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francois-Xavier Mahon .

Editor information

Editors and Affiliations

  1. Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

    Rüdiger Hehlmann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mahon, FX., Saußele, S. (2016). Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response. In: Hehlmann, R. (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-33198-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33198-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33197-3

  • Online ISBN: 978-3-319-33198-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation